Core Viewpoint - The article emphasizes the growing recognition and effectiveness of GLP-1 receptor agonists in managing obesity and type 2 diabetes, highlighting the transition from injectable to oral formulations as a key development for broader accessibility and patient adherence [4][12]. Injectable GLP-1 Agonists - Semaglutide and tirzepatide have shown significant clinical efficacy, with semaglutide leading to a weight reduction of approximately 10%-15% and a decrease in HbA₁c by about 1.5%-2.0% [4]. - Tirzepatide, as a dual agonist, demonstrates superior efficacy and has become a milestone in metabolic treatment [4]. - Despite the effectiveness of injectable forms, patient adherence is challenged by the complexity of administration, prompting ongoing improvements in injection devices [5]. Oral Semaglutide: PIONEER Series - Oral semaglutide (Rybelsus) is the first GLP-1 oral medication, with PIONEER studies indicating an average HbA₁c reduction of 1.0%-1.5% and a weight loss of about 4 kg over 52 weeks [6]. - Subgroup analyses in Chinese populations show that oral semaglutide outperforms sitagliptin in controlling HbA₁c and weight, with consistent safety profiles [8]. - The convenience of oral administration significantly enhances patient adherence, making it suitable for daily management [8]. Small Molecule Oral GLP-1: Future Market Potential - Eli Lilly's small molecule GLP-1 agonist Orforglipron shows promising oral stability and production advantages, with Phase 3 trials indicating an average weight loss of 7.3 kg and HbA₁c reduction of about 1.5% over 40 weeks [10]. - In larger studies, high-dose groups achieved a weight loss of 10.5% and over 75% of patients met diabetes remission criteria [10]. - The oral formulation's convenience may attract a broader patient base, with ongoing studies aimed at establishing local data support [10]. Pathway to Popularization of Oral GLP-1 - Oral GLP-1 medications are seen as pivotal for widespread adoption due to their alignment with daily lifestyles, cost-effectiveness, and improved patient adherence [12]. - The future trend is expected to involve both injectable and oral forms, focusing on personalized metabolic management [12]. - Collaborative efforts among companies, healthcare providers, and insurance sectors are essential to enhance the accessibility and affordability of GLP-1 treatments [12]. Outlook: Towards an Era of Oral GLP-1 - The next few years may witness the emergence of an "oral GLP-1 era" in China, driven by accelerated clinical progress, clear policy guidelines, and improved insurance coverage [14]. - This transformation is anticipated to elevate the management of metabolic diseases and contribute significantly to public health strategies [14]. - Companies that proactively develop high-quality products and services will play a leading role in this evolving landscape [14].